[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100625878":3},{"organization":4,"outcomesModule":7,"designInfo":44,"detailedDescription":53,"studyPopulation":49,"armGroups":54,"interventions":61,"overallOfficials":67,"centralContacts":71,"locations":79,"responsibleParty":114,"collaborators":49,"id":116,"slug":117,"hasResults":118,"nctId":119,"briefTitle":120,"officialTitle":121,"acronym":122,"eligibilityCriteria":123,"healthyVolunteers":118,"sex":124,"minAge":125,"maxAge":126,"enrollmentInfo":127,"targetDuration":49,"studyType":130,"phases":131,"briefSummary":132,"conditions":133,"keywords":135,"overallStatus":82,"whyStopped":49,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":147},{"fullName":5,"class":6},"National Cancer Centre, Singapore","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":17,"otherOutcomes":25},[9,13],{"measure":10,"description":11,"timeFrame":12},"6-month local control rate.","Proportion of patients with absence of local tumour progression at the treated site as per RECIST version 1.1 criteria.","6 months post-procedure.",{"measure":14,"description":15,"timeFrame":16},"Major complication rate.","Incidence of treatment-related adverse events (AEs) of grade ≥3 (CTCAE v5.0) within 30 days post-procedure.","30 days post-procedure.",[18,22],{"measure":19,"description":20,"timeFrame":21},"36-hour technical success rate.","Proportion of patients with tumour treated volume ≥ targeted volume with complete tumour coverage, evaluated using contrast-enhanced MRI\u002FCT.","36 hours post-procedure.",{"measure":23,"description":24,"timeFrame":16},"30-day technique efficacy rate.","Proportion of patients with absence of nodular or mass-like enhancement within or along the treatment volume",[26,30,34,37,41],{"measure":27,"description":28,"timeFrame":29},"Longitudinal Response Evaluation and patterns of progression.","Percentage change of tumour sizes from baseline to each of the timepoints specified in the protocol. Pattern of progression will be tabulation (frequency + percentages) of the pattern of progression","3 months, 6 months, 1 year and 2 years post-procedure.",{"measure":31,"description":32,"timeFrame":33},"Changes in quality-of-life post-histotripsy, based on EORTC QLQ-C30 scores.","Change of scores based on EORTC QLQ-C30 for liver malignancies from baseline to each of the timepoints specified in the protocol","30 days, 3 months, 6 months, 1 year and 2 years post-procedure.",{"measure":35,"description":36,"timeFrame":33},"Changes in quality-of-life post-histotripsy, based on EORTC QLQ-HCC18 scores.","Change of scores based on EORTC QLQ-HCC18 for liver malignancies from baseline to each of the timepoints specified in the protocol",{"measure":38,"description":39,"timeFrame":40},"Immune Response Analysis based on Information from Immune Biomarkers.","Evaluation of changes in circulating immune biomarkers post-histotripsy.","36 hours, 14 days, 30 days, 3 months and 6 months post-procedure.",{"measure":42,"description":43,"timeFrame":40},"Immune Response Analysis based on Information from Microbiome.","Evaluation of changes in circulating microbiome post-histotripsy.",{"allocation":45,"interventionModel":46,"interventionModelDescription":47,"primaryPurpose":48,"observationalModel":49,"timePerspective":49,"maskingInfo":50},"NA","SINGLE_GROUP","Histotripsy treatment.","TREATMENT",null,{"masking":51,"maskingDescription":52,"whoMasked":49},"NONE","Patients will undergo baseline imaging and laboratory investigations, followed by histotripsy treatment under general anaesthesia.","This will be a single-arm, multi-centre, prospective pilot study enrolling patients with:\n\nA) Liver limited malignancies (primary or secondary) not eligible for\u002Fdeclined resection or other locoregional treatment modalities.\n\nB) All solid cancer patients (e.g., HCC, colorectal, breast, pancreatic cancers etc) undergoing systemic therapy with oligoprogressive liver disease (defined as ≤ 3 liver limited progressive lesions, ≤ 3 cm in maximum diameter having received \\> 3 months of systemic therapy).\n\nPatients will undergo baseline imaging and laboratory investigations, followed by histotripsy treatment under general anaesthesia. Post-procedure assessments will be performed at predefined intervals for clinical, radiologic, and biomarker evaluation.",[55],{"label":56,"type":57,"description":58,"interventionNames":59},"Histotripsy Group","EXPERIMENTAL","Histotripsy for Ablation of Liver Tumours.",[60],"Device: Histotripsy using HistoSonics Edison™ System",[62],{"type":63,"name":64,"description":65,"armGroupLabels":66,"otherNames":49},"DEVICE","Histotripsy using HistoSonics Edison™ System","The histotripsy procedure will be performed using the HistoSonics Edison™ System, an image-guided, non-invasive focused ultrasound platform specifically designed for mechanical tissue fractionation. Key steps include general anaesthesia and positioning, pre-treatment planning and imaging, and histotripsy ablation procedure.",[56],[68],{"name":69,"affiliation":5,"role":70},"Prof Brian Goh, MBBS, MMed, MSc, FRCSEd, FAMS","PRINCIPAL_INVESTIGATOR",[72,76],{"name":69,"role":73,"phone":74,"phoneExt":49,"email":75},"CONTACT","+65 63265440","brian.goh@singhealth.com.sg",{"name":77,"role":73,"phone":49,"phoneExt":49,"email":78},"Sandra Hsing","sandra.hsing.san@nccs.com.sg",[80,96,104],{"facility":81,"status":82,"city":83,"state":49,"zip":84,"country":83,"countryCode":85,"cosmosGeoPoint":86,"geoPoint":91,"contacts":92},"National University Hospital","RECRUITING","Singapore","119074","SG",{"type":87,"coordinates":88},"Point",[89,90],103.85007,1.28967,{"lat":90,"lon":89},[93],{"name":94,"role":73,"phone":49,"phoneExt":49,"email":95},"Dr Shao-Jin ONG, MBBS, FRCR (UK), FAMS","shao_jin_ong@nuhs.edu.sg",{"facility":97,"status":82,"city":83,"state":49,"zip":98,"country":83,"countryCode":85,"cosmosGeoPoint":99,"geoPoint":101,"contacts":102},"National Cancer Centre Singapore","168583",{"type":87,"coordinates":100},[89,90],{"lat":90,"lon":89},[103],{"name":69,"role":73,"phone":74,"phoneExt":49,"email":75},{"facility":105,"status":82,"city":83,"state":49,"zip":106,"country":83,"countryCode":85,"cosmosGeoPoint":107,"geoPoint":109,"contacts":110},"Singapore General Hospital","169608",{"type":87,"coordinates":108},[89,90],{"lat":90,"lon":89},[111],{"name":112,"role":73,"phone":49,"phoneExt":49,"email":113},"A\u002FProf Chow Wei TOO, MBBS, FRCR, MMed, FAMS","too.chow.wei@singhealth.com.sg",{"type":115,"investigatorFullName":49,"investigatorTitle":49,"investigatorAffiliation":49,"oldNameTitle":49,"oldOrganization":49},"SPONSOR","100625878","histotripsy-for-ablation-of-liver-tumours-in-asia-100625878",false,"NCT07428356","Histotripsy for Ablation of Liver Tumours in Asia","Histotripsy Ablation for Liver Tumours (HALT): A Multi-centre Prospective Pilot Study on the Safety and Efficacy of Histotripsy in Asian Primary and Secondary Liver Malignancies","HALT","Inclusion Criteria:\n\n1. Age ≥21 years at the time of consent.\n2. Histologically\u002Fcytologically confirmed cancers (imaging diagnosis as per AASLD allowed for HCC):\n\n   A) Liver limited malignancies (primary or secondary) not eligible for\u002Fdeclined resection or other locoregional treatment modalities.\n\n   B) All solid cancer patients (e.g., HCC, colorectal, breast, pancreatic cancers etc) undergoing systemic therapy with oligoprogressive liver disease (defined as ≤ 3 liver limited progressive lesions, ≤ 3 cm in maximum diameter having received \\> 3 months of systemic therapy).\n3. Characteristics of hepatic lesions intended for treatment:\n\n   * Up to 3 hepatic lesions.\n   * Tumour ≤ 3 cm in longest diameter.\n   * Lesion(s) must be visible and targetable by ultrasound.\n4. ECOG Performance Status 0-1.\n5. Child-Pugh class A or B7 liver function for patients with underlying cirrhosis.\n6. Adequate hematologic and organ function within 14 days prior to treatment:\n\n   * Haemoglobin ≥ 9.0 g\u002FdL\n   * Platelets ≥ 75,000\u002Fmm³\n   * INR ≤ 1.5 × ULN\n   * Estimated (by Cockroft-Gault or Modification of Diet in Renal Disease (MDRD) or measured creatinine clearance ≥ 50ml\u002Fmin.\n   * Total bilirubin ≤ 1.5 × upper limit normal or direct bilirubin ≤ ULN for participants with total bilirubin \\> 1.5 × ULN (participants with known history of elevated indirect bilirubin level suggestive of extrahepatic source of elevation e.g. Gilbert's disease may be recruited with bilirubin levels ≤ 3 × ULN)\n   * AST and ALT ≤ 5 × ULN\n7. Ability to undergo general anaesthesia, as confirmed by pre-anaesthetic assessment.\n8. Life expectancy ≥ 3 months in the opinion of the investigator.\n9. Willing and able to comply with study visits and procedures.\n10. Written informed consent obtained prior to any study-related procedures.\n\nExclusion Criteria:\n\n1. Extrahepatic disease progression requiring immediate systemic intervention, including new brain metastases or malignant ascites.\n2. Vascular invasion, defined as gross involvement or encasement of major portal vein or hepatic vein branches.\n3. Tumours located adjacent (\\\u003C5 mm) to hollow viscera (e.g., stomach, colon) where histotripsy poses perforation risk.\n4. Lesions poorly visualized on ultrasound or not targetable due to overlying ribs or gas.\n5. Severe or uncontrolled comorbidities including:\n\n   * Uncontrolled hypertension or cardiovascular disease\n   * Active infection (requiring systemic therapy)\n   * Severe chronic obstructive pulmonary disease or hypoxia\n6. Contraindications to general anaesthesia or surgery.\n7. Pregnancy or breastfeeding. Women of childbearing potential must have a negative pregnancy test within 7 days prior to treatment.\n8. Participation in another interventional trial within 4 weeks prior to enrollment, or concurrent participation in a therapeutic study.\n9. Any condition that, in the investigator's judgment, may compromise the patient's safety or interfere with protocol adherence.","ALL","21 Years","99 Years",{"count":128,"type":129},40,"ESTIMATED","INTERVENTIONAL",[45],"The HALT study aims to evaluate histotripsy in an Asian population for both primary (HCC, CCA) and secondary liver malignancies with liver-limited or oligoprogressive disease. In addition to safety and local control, the study incorporates translational endpoints including immune profiling (PBMCs, cytokines), microbiome shifts, and optional tumour biopsies. This trial will provide critical data on the feasibility, tolerability, and biological impact of histotripsy in a region with the highest burden of liver cancer.",[134],"Liver Malignant Tumors",[136,137],"Histotripsy","Ablation of Liver Tumours","2026-10-07",{"date":140,"type":141},"2026-10-08","ACTUAL",{"date":143,"type":141},"2025-11-07",{"date":145,"type":129},"2029-05-07",{"name":5,"class":6},3]